Last reviewed · How we verify
NCT06782451: DST
Development of Preclinical Models Derived From Tumors With a Molecular Abnormality of Interest to Test Their Sensitivity to New Anti-tumor Therapies.
NA trial testing Surgery or biopsy in Neoplasm Malignant in 50 participants. Currently enrolling.
2 July 2030
Quick facts
| Lead sponsor | Centre Antoine Lacassagne |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 50 |
| Start date | 2 May 2025 |
| Primary completion | 2 July 2030 |
| Estimated completion | 2 July 2030 |
| Sites | 1 location across France |
Drugs / interventions tested
- Surgery or biopsy
- Blood sample — full drug profile →
Conditions studied
- Neoplasm Malignant — all drugs for Neoplasm Malignant →
Sponsor
Centre Antoine Lacassagne — full company profile →
Who can join
18 and older, any sex, with Neoplasm Malignant. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to collect tumor samples from patients carrying a mutation of interest to develop a cell culture technique for "spheroids. The goal is to use these spheroids to model responses to anticancer treatments. Various therapeutic molecules can be tested on these spheroids, enabling the evaluation of the potential of new molecules or the activity of existing ones specifically on the tumor (bearing the mutation of interest) from which the spheroid was developed. Tumor samples will be collected as part of biopsies or surgeries conducted during routine patient care.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06782451
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neoplasm Malignant
Currently open trials in the same condition.
- NCT07209111 — A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014) · Phase 2 · recruiting
- NCT06606366 — Study on the Contribution of the Genetic Tumor Profile Obtained by Circulating Tumor DNA Analysis in the Multidisciplina · NA · recruiting
- NCT06575127 — Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two · Phase 2 · recruiting
- NCT04987359 — A Trial of a Multimodal Lifestyle Intervention to Optimize Survivorship After Cancer · NA · active not recruiting
- NCT04976634 — Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) · Phase 2 · active not recruiting
Other Centre Antoine Lacassagne trials
Trials by the same sponsor.
- NCT07429487 — Assessment of Adherence to Remotely Monitored Physical Activity Tracked on a Smartwatch, and Its Impact on Reducing Fati · NA · not yet recruiting
- NCT06606366 — Study on the Contribution of the Genetic Tumor Profile Obtained by Circulating Tumor DNA Analysis in the Multidisciplina · NA · recruiting
- NCT06400849 — Comparison of the Efficacy of Cryotherapy Combined With Compression in Preventing Neuropathy · NA · recruiting
- NCT06029218 — Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy · NA · recruiting
- NCT06058312 — Individual Food Preferences for the Mediterranean Diet in Cancer Patients · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06782451 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Antoine Lacassagne
- Last refreshed: 29 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06782451.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing